The Missing Leg of UK Genomics

Some people present the UK as a powerhouse of genomics. Clearly, there are grounds for that assertion: Genomics England, Our Future Health, the UK Biobank, and the 100,000 Newborn project. These initiatives are trailblazing and leading on a global scale, making the UK an invaluable place for genomic research and development. However, if we are to truly make genomics a thriving sector, we must address the critical gap that still exists.

From the perspectives of government support, university involvement, and the NHS, the UK’s genomics sector appears robust and well-supported. Yet, when it comes to translating the wealth and breadth of knowledge into tangible economic growth, there is a noticeable shortfall. This shortfall is most evident in the areas of private investment, entrepreneurial activity, and the creation of a vibrant startup ecosystem.

To bridge this gap, we need to develop a better value proposition for investors. The potential of genomics as a source of wealth and economic development must be effectively communicated. Investors need to see the clear financial benefits and long-term value that genomic technologies can bring. This involves showcasing successful case studies, demonstrating the scalability of genomic solutions, and highlighting the market demand for personalised medicine and genomic data applications.

Moreover, we need more private investment to fuel innovation and drive the sector forward. Public funding and support have laid a strong foundation, but private capital is essential for scaling operations, commercialising research, and sustaining growth. Engaging with venture capitalists, angel investors, and corporate partners can provide the necessary financial backing to take genomics innovations from the lab to the market.

In addition, fostering a culture of entrepreneurship within the genomics sector is crucial. More support is needed for spin-offs and startups, providing mentorship, resources, and networking opportunities. Building incubators and accelerators specifically tailored to genomics can help nurture new companies and connect them with potential investors and collaborators. nd although there are a number of great initiatives that are supporting this kind of development such as Start Codon in Cambridge or KQ Labs at the Crick, there is still a slow churning of small companies that in my opinion needs to be revolutionised.

Ultimately, the UK has the potential to become a global leader in genomics, not just in research and healthcare, but also in economic terms. We need to think long and hard how to address the current gaps in investment and entrepreneurial activity, effectively conveying the value and potential of genomics, so that we can create a thriving ecosystem that benefits both the economy and society at large.